Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy.

Literature DB >> 30552446

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy.

Eric Guedj^1,2,3, Thomas Graillon^4,5, Olivier Chinot⁶, David Taieb^7,8,9.

Abstract

Entities: Disease

Mesh：

Substances：
Receptors, Peptide

Year: 2018 PMID： 30552446 DOI： 10.1007/s00259-018-4221-y

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

19 in total

1. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

Authors: Katharina Seystahl; Veit Stoecklein; Ulrich Schüller; Elisabeth Rushing; Guillaume Nicolas; Niklaus Schäfer; Harun Ilhan; Athina Pangalu; Michael Weller; Jörg-Christian Tonn; Michael Sommerauer; Nathalie L Albert
Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300

2. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.

Authors: Martijn van Essen; Eric P Krenning; Peter P Kooij; Willem H Bakker; Richard A Feelders; Wouter W de Herder; John G Wolbers; Dik J Kwekkeboom
Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057

3. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.

Authors: Karine Gerster-Gilliéron; Flavio Forrer; Helmut Maecke; Jan Mueller-Brand; Adrian Merlo; Dominik Cordier
Journal: J Nucl Med Date: 2015-08-20 Impact factor: 10.057

4. Personalized ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

Authors: Michela Del Prete; François-Alexandre Buteau; Jean-Mathieu Beauregard
Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-31 Impact factor: 9.236

Review 5. Correlation of dose with toxicity and tumour response to ⁹⁰Y- and ¹⁷⁷Lu-PRRT provides the basis for optimization through individualized treatment planning.

Authors: Marta Cremonesi; Mahila Esmeralda Ferrari; Lisa Bodei; Carlo Chiesa; Anna Sarnelli; Cristina Garibaldi; Massimiliano Pacilio; Lidia Strigari; Paul Eugene Summers; Roberto Orecchia; Chiara Maria Grana; Francesca Botta
Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-21 Impact factor: 9.236

Review 6. PET imaging in patients with meningioma-report of the RANO/PET Group.

Authors: Norbert Galldiks; Nathalie L Albert; Michael Sommerauer; Anca L Grosu; Ute Ganswindt; Ian Law; Matthias Preusser; Emilie Le Rhun; Michael A Vogelbaum; Gelareh Zadeh; Frédéric Dhermain; Michael Weller; Karl-Josef Langen; Jörg C Tonn
Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300

7. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.

Authors: Mirco Bartolomei; Lisa Bodei; Concetta De Cicco; Chiara Maria Grana; Marta Cremonesi; Edoardo Botteri; Silvia Melania Baio; Demetrio Aricò; Maddalena Sansovini; Giovanni Paganelli
Journal: Eur J Nucl Med Mol Imaging Date: 2009-03-25 Impact factor: 9.236

8. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.

Authors: Michael C Kreissl; Heribert Hänscheid; Mario Löhr; Frederik A Verburg; Markus Schiller; Michael Lassmann; Christoph Reiners; Samuel S Samnick; Andreas K Buck; Michael Flentje; Reinhart A Sweeney
Journal: Radiat Oncol Date: 2012-06-21 Impact factor: 3.481

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy.

1. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.

2. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.

3. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.

4. Personalized ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study.

Review 5. Correlation of dose with toxicity and tumour response to ⁹⁰Y- and ¹⁷⁷Lu-PRRT provides the basis for optimization through individualized treatment planning.

Review 6. PET imaging in patients with meningioma-report of the RANO/PET Group.

7. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.

8. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma.

9. Successful radiopeptide targeting of metastatic anaplastic meningioma: case report.

10. Individualised ¹⁷⁷Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry.

Review 1. PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area.

Review 5. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning.

Review 6. PET imaging in patients with meningioma-report of the RANO/PET Group.

Review 1. PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area.

Review 5. Correlation of dose with toxicity and tumour response to ⁹⁰Y- and ¹⁷⁷Lu-PRRT provides the basis for optimization through individualized treatment planning.